CN115607760A - Activated leukocyte adsorber - Google Patents
Activated leukocyte adsorber Download PDFInfo
- Publication number
- CN115607760A CN115607760A CN202110803083.8A CN202110803083A CN115607760A CN 115607760 A CN115607760 A CN 115607760A CN 202110803083 A CN202110803083 A CN 202110803083A CN 115607760 A CN115607760 A CN 115607760A
- Authority
- CN
- China
- Prior art keywords
- adsorption film
- adsorption
- blood
- activated leukocyte
- adsorber
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000265 leukocyte Anatomy 0.000 title claims abstract description 31
- 238000001179 sorption measurement Methods 0.000 claims abstract description 96
- 239000012528 membrane Substances 0.000 claims abstract description 23
- 210000004369 blood Anatomy 0.000 claims abstract description 16
- 239000008280 blood Substances 0.000 claims abstract description 16
- 230000017531 blood circulation Effects 0.000 claims abstract description 11
- 239000006096 absorbing agent Substances 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims abstract description 3
- 239000011162 core material Substances 0.000 claims description 11
- 238000003466 welding Methods 0.000 claims description 6
- 239000012620 biological material Substances 0.000 claims description 3
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 abstract description 9
- 230000006378 damage Effects 0.000 abstract description 5
- 239000012503 blood component Substances 0.000 abstract description 3
- 238000002615 hemofiltration Methods 0.000 abstract description 3
- 230000007420 reactivation Effects 0.000 abstract description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 6
- 230000000770 proinflammatory effect Effects 0.000 description 5
- 230000004087 circulation Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 210000001772 blood platelet Anatomy 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000004804 winding Methods 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3496—Plasmapheresis; Leucopheresis; Lymphopheresis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/16—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis with membranes
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- External Artificial Organs (AREA)
Abstract
The invention provides an activated leukocyte absorber, which comprises end covers, a shell and an adsorption film, wherein the end covers are connected with the two ends of the shell to form a closed cavity, the shell wraps the adsorption film, the adsorption film is positioned in the closed cavity, one end cover is provided with a blood inflow port, and the other end cover is provided with a blood outflow port; the method is characterized in that: the both ends of adsorption film are connected with adsorption film bearing structure respectively, and adsorption film bearing structure is the cavity pipeline structure of evenly arranging, the spiral arrangement is rolled up to the adsorption film, and adsorption film bearing structure supports adjacent two-layer adsorption film, forms the clearance between each layer, and blood flows in the adsorption film reel through these cavity pipelines. When the activated leukocyte adsorber of the invention is used for purifying the blood of a SIRS patient, the blood flows through the adsorption membranes to replace a hemofiltration mode, and the adsorption membranes selectively adsorb and remove activated leukocytes, simultaneously can reduce the damage and reactivation of the leukocytes, and does not influence other blood components of the patient.
Description
Technical Field
The invention relates to the field of medical instruments, in particular to an activated leukocyte adsorber.
Background
Systemic Inflammatory Response Syndrome (SIRS) is an inflammatory syndrome caused by a variety of diseases (e.g., sepsis, viral infection, trauma, extracorporeal circulation), with the pathogenesis of injury arising from uncontrolled activation of inflammatory cells and entry into tissues, with release of large amounts of proinflammatory factors to exert an inflammatory amplification effect. SIRS patients have high organ failure rate and high mortality rate, and an effective treatment means is lacked at present. Current intervention strategies for SIRS focus on systemic administration to suppress the inflammatory response, but this indiscriminate suppression of the body's inflammatory and normal immune responses results in the protocol ending up as a negative result in clinical trials. Inflammation-related substance adsorption is another strategy for treating SIRS, and proinflammatory factor adsorbers (such as
) Applied to the clinic, because proinflammatory factors are subordinate to inflammatory cells in SIRS generation, only limited therapeutic effect is shown in the clinic; proinflammatory factors are mainly released by activated inflammatory cells and play a main role in organ injury, so theoretically, the effect of eliminating the activated inflammatory cells is better than that of removing the proinflammatory factors. To remove these inflammatory cells, leukocyte filters are currently used, whose principle is: when blood passes through a filter membrane, a large number of leukocytes are "screened out" and thus it is not possible to selectively remove activated inflammatory cells, and such a filter may lead to an exacerbation of the patient's condition and is not suitable for clinical use.
Disclosure of Invention
In order to solve the defects in the prior art, the invention provides an activated leukocyte adsorber, wherein a filtering membrane is changed into a winding drum type adsorption membrane, blood flows through the adsorption membrane, a hemofiltration mode is replaced, when leukocytes contact the surface of the adsorption membrane, activated leukocytes with strong adhesive capacity are adhered to the adsorption membrane and then removed, but unactivated leukocytes smoothly pass through the adsorber due to lack of adhesive property, so that the removed cells are mainly activated leukocytes.
In order to achieve the technical purpose, the technical scheme adopted by the invention is as follows:
an activated leukocyte absorber comprises end covers, a shell and an adsorption film, wherein the end covers are connected with two ends of the shell to form a closed cavity, the shell wraps the adsorption film, the adsorption film is positioned in the closed cavity, one end cover is provided with a blood inflow port, and the other end cover is provided with a blood outflow port; the method is characterized in that: the both ends of adsorption film are connected with adsorption film bearing structure respectively, and adsorption film bearing structure is the cavity pipeline structure of evenly arranging, the adsorption film coils the heliciform and arranges, and adsorption film bearing structure supports adjacent two-layer adsorption film, forms the clearance between each layer, and blood flows in the adsorption film reel through these cavity pipelines.
Preferably, the adsorption membrane support structure is a hollow circular tube.
Preferably, the adsorption film support structure is a hollow triangular prism pipe.
The adsorption film further comprises an adsorption film inner support core, and the adsorption film is coiled into a spiral arrangement by taking the adsorption film inner support core as a core material.
Furthermore, the adsorption membrane is an activated leukocyte adsorption membrane, and the material of the adsorption membrane is a high molecular biological material.
Furthermore, the end cover and the shell are connected by welding in an ultrasonic welding mode, and the adsorption film support structure are connected by adhesion.
Compared with the prior art, the invention has the beneficial effects that:
1) When the activated leukocyte adsorber of the invention is used for purifying blood of a SIRS patient, the blood flows through the adsorption membranes, the blood filtration mode is replaced, the adsorption membranes selectively adsorb and remove activated leukocytes, meanwhile, the damage and reactivation of the leukocytes can be reduced, and other blood components (such as red blood cells, platelets and lymphocytes) of the patient are not influenced.
2) According to the activated leukocyte adsorber disclosed by the invention, the two ends of the adsorption film are respectively connected with the hollow adsorption film supporting structures, the adsorption film supporting structures support two adjacent layers of the spirally arranged adsorption film, gaps are formed between the layers, and blood flows into the adsorption film winding drum through the hollow pipelines, so that on one hand, the adsorption film supporting structures play a supporting role to avoid adhesion of the adsorption film, on the other hand, the blood can be in contact with the two sides of the adsorption film, the utilization rate of the adsorption film is improved, and the adsorption effect is good.
Drawings
To more clearly illustrate the technical solutions of the embodiments of the present application, the drawings needed in the embodiments will be briefly described below, it should be understood that the following drawings only illustrate some embodiments of the present application and therefore should not be considered as limiting the scope, and those skilled in the art can also obtain other related drawings based on the drawings without inventive efforts.
FIG. 1 is a schematic structural diagram of a first embodiment of the present invention;
FIG. 2 is a cross-sectional view of the first embodiment shown in FIG. 1;
FIG. 3 is a schematic structural diagram of a second embodiment of the present invention;
FIG. 4 is a cross-sectional view of the second embodiment shown in FIG. 3;
FIG. 5 is a developed view of an absorbent film of the first embodiment shown in FIG. 1;
fig. 6 is a developed view of an absorbent film of the second embodiment shown in fig. 3.
Reference numerals: 1-outflow port, 2-end cover, 3-shell, 4-adsorption film, 5-adsorption film inner support core, 6-adsorption film support structure and 7-inflow port.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present application clearer, the technical solutions in the embodiments of the present application will be clearly and completely described below with reference to the drawings in the embodiments of the present application, and it is obvious that the described embodiments are some embodiments of the present application, but not all embodiments. The components of the embodiments of the present application, as generally described and illustrated in the figures herein, could be arranged and designed in a wide variety of different configurations.
The invention discloses an activated leukocyte absorber, which comprises end covers 2, a shell 3 and an adsorption film 4, wherein the end covers 2 are connected with two ends of the shell 3 to form a closed cavity, the shell 3 wraps the adsorption film 4, the adsorption film 4 is positioned in the closed cavity, one end cover 2 is provided with a blood inflow port 7, and the other end cover 2 is provided with a blood outflow port 1; the both ends of adsorption film 4 are connected with adsorption film bearing structure 6 respectively, and adsorption film bearing structure 6 is the hollow circular or triangular prism or the wave pipeline structure of evenly arranging, adsorption film 4 supports core 5 as the core in with the adsorption film, perhaps need not the direct spiral of coiling of core and arranges, and adsorption film bearing structure 6 supports adjacent two-layer adsorption film, forms the clearance between each layer, and blood flows in the adsorption film reel through these cavity pipelines.
The adsorption film 4 is an activated leukocyte adsorption film made of a high-molecular biological material, and the adsorption film support structure 6 is made of a high-molecular synthetic material.
The connection between end cover 2 and shell 3 is the welding, and the welding mode is ultrasonic bonding, support core 5 and adsorption film bearing structure 6's connection in adsorption film 4, the adsorption film is the adhesion.
When in use, the activated leucocyte connects the absorber into the extracorporeal circulation pipeline of a patient, blood flows in from the inflow port 7 and flows into the interior of the adsorption membrane reel through the hollow pipeline in the adsorption membrane supporting structure 6 at the inflow port end; blood flows through the adsorption membranes from the two adjacent layers inside the adsorption membranes, activated leucocytes are adsorbed by the adsorption membranes, and the purified blood flows through the hollow pipeline of the adsorption membrane supporting structure 6 at the end of the outflow port 1 and then flows out through the blood outflow port to return to the body of a patient, so that circulation is realized.
The activated leukocyte adsorber of the invention can reduce the damage and reactivation of leukocytes while selectively adsorbing and removing activated leukocytes by replacing a hemofiltration mode through the blood flowing between adsorption membranes when purifying the blood of SIRS patients, and does not influence other blood components (such as red blood cells, platelets and lymphocytes) of the patients.
The present invention is capable of other embodiments, and various changes and modifications can be made by one skilled in the art without departing from the spirit and scope of the invention.
Claims (6)
1. An activated leukocyte absorber comprises end covers (2), shells (3) and an adsorption film (4), wherein the end covers (2) are connected with the two ends of the shells (3) to form a closed cavity, the shells (3) wrap the adsorption film (4), the adsorption film (4) is positioned in the closed cavity, one end cover (2) is provided with a blood inflow port (7), and the other end cover (2) is provided with a blood outflow port (1); the method is characterized in that: the both ends of adsorption film (4) are connected with adsorption film bearing structure (6) respectively, and adsorption film bearing structure (6) are the cavity pipeline structure of evenly arranging, adsorption film (4) batching heliciform is arranged, and adsorption film bearing structure (6) support adjacent two-layer adsorption film, forms the clearance between each layer, and blood flows in the adsorption film reel through these cavity pipelines.
2. The activated leukocyte adsorber of claim 1 wherein: the adsorption membrane support structure (6) is a hollow circular pipe.
3. The activated leukocyte adsorber of claim 1 wherein: the adsorption membrane support structure (6) is a hollow triangular prism pipe.
4. The activated leukocyte adsorber of claim 2 or 3 wherein: the adsorption film is characterized by further comprising an adsorption film inner supporting core (5), and the adsorption film (4) is coiled into a spiral arrangement by taking the adsorption film inner supporting core (5) as a core material.
5. The activated leukocyte adsorber of claim 1 wherein: the adsorption film (4) is an activated leukocyte adsorption film made of a high molecular biological material.
6. The activated leukocyte adsorber of claim 1 wherein: the connection between end cover (2) and shell (3) is the welding, and the welding mode is ultrasonic bonding, adsorption film (4) and adsorption film bearing structure (6) are connected for the adhesion.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110803083.8A CN115607760A (en) | 2021-07-15 | 2021-07-15 | Activated leukocyte adsorber |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110803083.8A CN115607760A (en) | 2021-07-15 | 2021-07-15 | Activated leukocyte adsorber |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115607760A true CN115607760A (en) | 2023-01-17 |
Family
ID=84855514
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110803083.8A Pending CN115607760A (en) | 2021-07-15 | 2021-07-15 | Activated leukocyte adsorber |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN115607760A (en) |
-
2021
- 2021-07-15 CN CN202110803083.8A patent/CN115607760A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7758533B2 (en) | Hemofiltration systems, methods and devices for treatment of chronic and acute diseases | |
| US8123940B2 (en) | Filtration unit for the selective elimination of a target substance | |
| US4206050A (en) | Membrane unit and apparatus for removing metabolite contaminants from blood | |
| CN204275132U (en) | A kind of apparatus for purifying blood that synchronously can realize dialysing and perfusion is treated | |
| US20010051106A1 (en) | Hemofiltration systems, methods and devices used to treat inflammatory mediator related disease | |
| WO2008038785A1 (en) | Cell-adsorbing column | |
| JP2009529386A (en) | Renewable filter and its use for extracorporeal treatment of liquid containing particles | |
| CN101657224B (en) | Assembly device for purifying blood | |
| CN215821881U (en) | Activated leukocyte adsorber | |
| WO2000038763A1 (en) | Method for purifying blood and column for purifying blood | |
| CN115607760A (en) | Activated leukocyte adsorber | |
| JPS62243561A (en) | Leucocyte removing filter device | |
| JP5017996B2 (en) | Leukocyte and cytokine adsorber | |
| JP4997770B2 (en) | Adsorber | |
| CN109689124B (en) | Liver support system | |
| JP5188280B2 (en) | Blood cell removal module | |
| WO2020151228A1 (en) | Method for preparing antibacterial hollow fiber membrane for blood purification | |
| CN217187201U (en) | Plasma filtering device for removing inflammatory factors | |
| CN115518219A (en) | Low-capacity activated leukocyte adsorber | |
| JP2017525489A (en) | Inflammatory mediators and systems for removing granulocytes and monocytes from blood | |
| US20040199099A1 (en) | Hemofiltration systems, methods and devices used to treat inflammatory mediator related disease | |
| CN213219787U (en) | Blood purification device | |
| CN108175888B (en) | Blood toxin adsorber | |
| WO2003009885A2 (en) | Hemofiltration systems, methods and devices used to treat inflammatory mediator related disease | |
| CN209075645U (en) | Blood toxicity absorber |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20231227 Address after: No. 1506, 15th Floor, Building 1, No. 1800 Yizhou Avenue Middle Section, Chengdu High tech Zone, China (Sichuan) Pilot Free Trade Zone, Chengdu City, Sichuan Province, 610000 Applicant after: Chengdu Shangyuantai Biotechnology Co.,Ltd. Address before: No. 37, Wuhou District National School Lane, Chengdu, Sichuan Province Applicant before: WEST CHINA HOSPITAL, SICHUAN University |